Pregnancy, Lactation, and Adverse Drug Effects

Pregnancy, lactation, and adverse drug effects concerns the distinctive safety considerations that arise when a medicine is taken by a pregnant or breastfeeding person, because exposure may reach not only the patient but also the developing embryo, fetus, or nursing infant. The physiological changes of pregnancy alter how the body handles drugs, and some agents can cross the placenta or pass into milk and cause harm, making this one of the most carefully studied risk contexts in pharmacovigilance.

Definition

Pregnancy, lactation, and adverse drug effects refers to the adverse outcomes a medicine may cause for the embryo, fetus, or breastfed infant through maternal exposure, together with the altered maternal pharmacokinetics of pregnancy that modify drug handling and risk.

Scope

The topic covers maternal-fetal and lactation drug exposure: the placental transfer and milk passage of drugs, the concept of teratogenicity and the importance of timing during gestation, and the pregnancy-related physiological changes that modify drug handling. It is a reference account of why pregnancy and lactation create special safety concerns and how the evidence is generated; it gives no advice on whether any specific drug should be used or avoided in an individual.

Core questions

• How can a drug taken by a pregnant or breastfeeding person affect the fetus or infant?
• What is teratogenicity and why does the timing of exposure during gestation matter?
• How do the physiological changes of pregnancy alter drug handling?
• Why is safety evidence in pregnancy and lactation often limited, and how is it gathered?

Key concepts

• Placental drug transfer
• Teratogenicity
• Critical periods of organogenesis
• Drug passage into breast milk
• Pregnancy-related pharmacokinetic changes
• Maternal-fetal risk-benefit framing
• Pregnancy exposure registries
• Limited evidence and exclusion from trials

Mechanisms

Risk in this setting arises from exposure crossing biological barriers combined with altered maternal drug handling. Many drugs cross the placenta and can reach the developing conceptus; whether exposure causes structural malformation depends heavily on the agent, the dose, and the timing relative to organogenesis, which defines critical windows of vulnerability. The classic demonstration is thalidomide, which produced characteristic limb-reduction defects when taken during a specific gestational window, establishing teratogenicity as a central drug-safety concept (Lenz, 1988). During lactation, drugs can pass into breast milk and reach the nursing infant in variable amounts. Pregnancy also changes maternal pharmacokinetics — increased volume of distribution and renal clearance, altered protein binding and metabolism — so drug exposure in the mother herself may differ from the non-pregnant state, paralleling how physiological state modifies drug handling more generally (Mangoni & Jackson, 2003).

Clinical relevance

Because both mother and offspring can be affected and because controlled trials usually exclude pregnant participants, much safety knowledge here comes from observational studies and registries, and uncertainty is often substantial. Studies such as case-control analyses of specific drug classes and birth defects illustrate how associations are investigated (Broussard et al., 2011). This entry explains why pregnancy and lactation create distinctive safety concerns and how evidence is built; it is descriptive and does not advise on using or avoiding any medicine in pregnancy or breastfeeding.

Epidemiology

Evidence on drug safety in pregnancy and lactation is frequently sparse because pregnant and breastfeeding people are commonly excluded from clinical trials, so post-marketing observational designs, exposure registries, and case-control studies of specific malformations carry much of the evidentiary weight (Broussard et al., 2011). The thalidomide episode remains the defining example of how a teratogenic signal emerged from clinical observation (Lenz, 1988).

History

The thalidomide tragedy of the late 1950s and early 1960s, in which a widely used sedative caused thousands of birth defects, transformed drug regulation and made teratogenicity and maternal-fetal drug safety a permanent focus of pharmacovigilance (Lenz, 1988). Subsequent decades saw the growth of pregnancy exposure registries and observational methods to study associations between maternal medication use and adverse outcomes (Broussard et al., 2011).

Debates

How should safety evidence be generated when trials exclude pregnant people?

Routine exclusion of pregnant and breastfeeding participants leaves a persistent evidence gap, prompting reliance on registries and observational designs and ongoing discussion about how to study drug safety in these populations responsibly.

Seminal works

• lenz-1988
• broussard-2011

Frequently asked questions

Why does timing matter for drug exposure in pregnancy?

The developing organs form during specific windows of gestation, so an exposure during a critical period of organogenesis can cause structural defects that the same exposure at another time might not, as the thalidomide experience showed.

Why is there often little safety information for medicines in pregnancy?

Pregnant and breastfeeding people are usually excluded from clinical trials, so much of the available knowledge comes from observational studies and exposure registries rather than controlled experiments, leaving more uncertainty.